Brief: Ovid Therapeutics Enters Agreement With Immedica Pharma AB For Sale Of Future Ganaxolone Royalties
25/06/2025 13:22
June 25 (Reuters) - Ovid Therapeutics Inc OVID.O: OVID THERAPEUTICS ENTERS AGREEMENT WITH IMMEDICA PHARMA AB FOR SALE OF FUTURE GANAXOLONE ROYALTIES OVID THERAPEUTICS INC - IMMEDICA TO PAY $7 MILLION FOR GANAXOLONE ROYALTY RIGHTS Source text: ID:nGNX68cc23 Further company coverage: OVID.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ovid Therapeutics
See all newsOvid Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Ovid Therapeutics Q2 revenue beats estimates
Brief: Ovid Therapeutics Q2 EPS USD -0.08
Ovid Therapeutics Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Ovid Therapeutics Appoints Leading Physician-Scientist And Biotech Innovator Anna Greka, M.D., Ph.D., To Board Of Directors